Cargando…

Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma

BACKGROUND: IDH-mutant lower-grade gliomas (LGGs) evolve under the selective pressure of therapy, but well-characterized patient-derived cells (PDCs) modeling evolutionary stages are lacking. IDH-mutant LGGs may develop therapeutic resistance associated with chemotherapy-driven hypermutation and mal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, Lindsey E, Hilz, Stephanie, Grimmer, Matthew R, Mazor, Tali, Najac, Chloé, Mukherjee, Joydeep, McKinney, Andrew, Chow, Tracy, Pieper, Russell O, Ronen, Sabrina M, Chang, Susan M, Phillips, Joanna J, Costello, Joseph F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462278/ https://www.ncbi.nlm.nih.gov/pubmed/32904945 http://dx.doi.org/10.1093/noajnl/vdaa088

Ejemplares similares

Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma
por: Radoul, Marina, et al.
Publicado: (2021)

Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters
por: Viswanath, Pavithra, et al.
Publicado: (2016)

MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma
por: Molloy, Abigail R, et al.
Publicado: (2020)

Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures
por: Verheul, Cassandra, et al.
Publicado: (2021)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

CBMS-1 TARGETING GLUTAMINE METABOLISM IN IDH-MUTANT GLIOMAS
por: Ohba, Shigeo, et al.
Publicado: (2022)

Monitoring response to a clinically relevant IDH inhibitor in glioma—Hyperpolarized (13)C magnetic resonance spectroscopy approaches
por: Hong, Donghyun, et al.
Publicado: (2023)

Metabolic Reprogramming in Mutant IDH1 Glioma Cells
por: Izquierdo-Garcia, Jose L., et al.
Publicado: (2015)

PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival
por: Batsios, Georgios, et al.
Publicado: (2019)

Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas
por: Cano-Galiano, Andrés, et al.
Publicado: (2021)

IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas
por: Zhang, Lei, et al.
Publicado: (2018)

Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks
por: Li, Kay Ka-Wai, et al.
Publicado: (2019)

Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1
por: Alghamri, Mahmoud S, et al.
Publicado: (2020)

Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring
por: Chaumeil, Myriam M., et al.
Publicado: (2016)

Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort
por: van Garderen, Karin A, et al.
Publicado: (2023)

Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression
por: Givechian, Kevin B, et al.
Publicado: (2020)

Deep learning super-resolution magnetic resonance spectroscopic imaging of brain metabolism and mutant isocitrate dehydrogenase glioma
por: Li, Xianqi, et al.
Publicado: (2022)

Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner
por: Viswanath, Pavithra, et al.
Publicado: (2018)

MRI-based classification of IDH mutation and 1p/19q codeletion status of gliomas using a 2.5D hybrid multi-task convolutional neural network
por: Chakrabarty, Satrajit, et al.
Publicado: (2023)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma
por: Zhang, Liang, et al.
Publicado: (2022)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma
por: Duchatel, Ryan J, et al.
Publicado: (2021)

Prognostic risk stratification of gliomas using deep learning in digital pathology images
por: Chunduru, Pranathi, et al.
Publicado: (2022)

Spatial concordance of DNA methylation classification in diffuse glioma
por: Verburg, Niels, et al.
Publicado: (2021)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Stalled oligodendrocyte differentiation in IDH-mutant gliomas
por: Wei, Yanfei, et al.
Publicado: (2023)

Updates on the WHO diagnosis of IDH-mutant glioma
por: Reuss, David.E.
Publicado: (2023)

TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors
por: Cantero, Diana, et al.
Publicado: (2020)

Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status
por: Unger, Kristian, et al.
Publicado: (2020)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Pyruvate Kinase M2 Expression, but Not Pyruvate Kinase Activity, Is Up-Regulated in a Grade-Specific Manner in Human Glioma
por: Mukherjee, Joydeep, et al.
Publicado: (2013)

Glioma-associated microglia/macrophages augment tumorigenicity in canine astrocytoma, a naturally occurring model of human glioma
por: Toedebusch, Ryan, et al.
Publicado: (2021)

ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma
por: Babikir, Husam, et al.
Publicado: (2021)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

Mutant IDH1 Promotes Glioma Formation In Vivo
por: Philip, Beatrice, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lg52r521thgr2lb6vfk68ddppv